Patents by Inventor Silvina Garcia-Rubio

Silvina Garcia-Rubio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12005056
    Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 11, 2024
    Assignee: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
  • Patent number: 11884646
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: January 30, 2024
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
  • Publication number: 20230158007
    Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
    Type: Application
    Filed: March 14, 2019
    Publication date: May 25, 2023
    Applicant: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
  • Publication number: 20220340541
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Application
    Filed: March 7, 2022
    Publication date: October 27, 2022
    Applicant: Helsinn Healthcare SA
    Inventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
  • Patent number: 11299472
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 12, 2022
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
  • Patent number: 10905737
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: February 2, 2021
    Assignees: Helsinn Healthcare SA, Ono Pharmaceutical Co., Ltd.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20200299260
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Application
    Filed: December 7, 2018
    Publication date: September 24, 2020
    Applicant: Helsinn Healthcare SA
    Inventors: Silvina GARCIA RUBIO, Mauro PERSEGHINI, Angelo GUAINAZZI, Claudio PIETRA, Claudio GIULIANO
  • Publication number: 20200276259
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: January 24, 2020
    Publication date: September 3, 2020
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20200262850
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 24, 2020
    Publication date: August 20, 2020
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Patent number: 10577384
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 3, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Patent number: 10576122
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 14, 2019
    Date of Patent: March 3, 2020
    Assignees: Helsinn Healthcare SA, Ono Pharmaceutical Co., Ltd.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 10407390
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: September 10, 2019
    Assignee: Helsinn Healthcare SA
    Inventors: Silvina Garcia Rubio, Claudio Pietra, Claudio Giuliano, Zhigang Li
  • Publication number: 20190231843
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 14, 2019
    Publication date: August 1, 2019
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 10300105
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 28, 2019
    Assignees: ONO PHARMACEUTICAL CO., LTD, HELSINN HEALTHCARE SA
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20190062352
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: February 28, 2019
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Publication number: 20190000914
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 26, 2018
    Publication date: January 3, 2019
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9981002
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 29, 2018
    Assignees: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9956261
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 1, 2018
    Assignees: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9926337
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 27, 2018
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Publication number: 20180044293
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Application
    Filed: July 30, 2017
    Publication date: February 15, 2018
    Inventors: Silvina GARCIA RUBIO, Claudio PIETRA, Claudio GIULIANO, Zhigang LI